Inactive Instrument

News Sarepta Therapeutics Inc Nasdaq

Equities

US0023461041

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 21	FDA greenlights Italfarmaco's drug for rare muscular dystrophy	RE
Mar. 12	Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition	Apr. 04	AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 29, 2024	Apr. 01	AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 29	BU
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	Mar. 21	RE
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program	Mar. 20	AQ
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM	Mar. 12
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	Mar. 12	MT
Transcript : Sarepta Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:00 AM	Mar. 11
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	Mar. 07	MT
Sarepta Therapeutics to Present at Upcoming Investor Conferences	Mar. 04	BU
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating	Mar. 01	MT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 01	AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 29	BU
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says	Feb. 29	MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating	Feb. 29	MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating	Feb. 29	MT
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program	Feb. 29	BU
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating	Feb. 29	MT
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	Feb. 28	MT
Transcript : Sarepta Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sarepta Therapeutics Inc Nasdaq

Equities

US0023461041

Summary

Filters